Cancer drug nivolumab tested in rare blood cancer
NCT ID NCT06936943
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug nivolumab (Opdivo) in 14 people with Richter's transformation, a rare and aggressive blood cancer that arises from chronic lymphocytic leukemia. The study measures how many patients respond to treatment, how long they live, and safety. All participants receive nivolumab every 4 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo)
What this could lead to
If it works, this could offer a new treatment option for Richter's transformation, a rare and aggressive blood cancer.
What could go wrong
This is a small, early-phase study with only 14 participants, so results may not apply broadly. Nivolumab can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RICHTER'S TRANSFORMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center
RECRUITINGNagoya, Aichi-ken, Japan
-
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
RECRUITINGHiroshima, Hiroshima, Japan
-
Hokkaido University Hospital
RECRUITINGSapporo, Hokkaido, 060-8648, Japan
-
Kindai University Hospital
RECRUITINGŌsaka-sayama, Osaka, Japan
-
Kyoto University Hospital
RECRUITINGKyoto, Kyoto, Japan
-
Kyusyu University Hospital
RECRUITINGFukuoka, Fukuoka, 812-8582, Japan
-
National Cancer Center Hospital
RECRUITINGChuo Ku, Tokyo, Japan
-
Niigata University Medical & Dental Hospital
RECRUITINGNiigata, Niigata, Japan
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, Japan
-
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
RECRUITINGBunkyō-Ku, Tokyo, Japan